Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Welcome to the POTP board, the DPP-IV company -- Ignore unavailable to you. Want to Upgrade?

To: rareearth42 who wrote (10)	8/4/2006 1:12:35 PM
From: former_pgs	Read Replies (1) \| Respond to of 90

I agree that the CRs look good. I'm a big fan of them, not just because they are rare in NSCLC, but also because they are rather unambiguous. However, I feel that the company has crippled itself with the registration plan in NSCLC. I have doubts as to the utility of showing a 1 month increase in PFS in a treatment setting that has drugs with proven survival benefits. In fact, it is 1 year survival that appears to be talabostat's most impressive / unambiguous efficacy demonstration to date (i think PFS comparisons between trials are especially problematic due to differences in follow-up intervals). Seems to me that the savings from following their patients for PFS rather than overall survival may turn out to be costly vis-a-vis approval.